Combining nivolumab with brentuximab vedotin (anti‐CD30 antibody–drug conjugate) increased CR rate to 61% in the interim analysis of a Phase 1/2 study of relapsed/refractory patients with cHL.27 The gene discussed is TNFRSF8; the disease is classic Hodgkin lymphoma.